Jon J Hangeland

Years Active: 2019-2021
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Huji Turdi, Hannguang Chao, Jon J Hangeland, Saleem Ahmad, Wei Meng, Robert Brigance, Guohua Zhao, Wei Wang, Fang Moore, Xiang-Yang Ye, Arvind Mathur, Xiaoping Hou, James Kempson, Dauh-Rurng Wu, Yi-Xin Li, Anthony V Azzara, Zhengping Ma, Ching-Hsuen Chu, Luping Chen, Mary Jane Cullen, Suzanne Rooney, Susan Harvey, Lisa Kopcho, Reshma Panemangelor, Lynn Abell, Kevin O'Malley, William J Keim, Elizabeth Dierks, Shu Chang, Kimberly Foster, Atsu Apedo, David Harden, Marta Dabros, Qi Gao, Mary Ann Pelleymounter, Jean M Whaley, Jeffrey A Robl, Dong Cheng, R Michael Lawrence, Pratik Devasthale
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders. Journal of medicinal chemistry 64 (19) (2021)
Michael M Miller, Jacques Banville, Todd J Friends, Mark Gagnon, Jon J Hangeland, Jean-François Lavallée, Alain Martel, Harold O'Grady, Roger Rémillard, Edward Ruediger, François Tremblay, Shana L Posy, Nick J Allegretto, Victor R Guarino, David G Harden, Timothy W Harper, Karen Hartl, Jonathan Josephs, Sarah Malmstrom, Carol Watson, Yanou Yang, Ge Zhang, Pancras Wong, Jing Yang, Michel Bouvier, Dietmar A Seiffert, Ruth R Wexler, R Michael Lawrence, E Scott Priestley, Anne Marinier
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy. Journal of medicinal chemistry 62 (16) (2019)

Jon J Hangeland.css-eqlu8i{font-size:small;padding-left:4px;}